AI assurance collapses when human verification is treated purely as a signature collection process. If challenging or rejecting an AI draft is awkward, slow, or organizationally discouraged, genuine oversight does not exist. Effective control is an organizational design challenge requiring teams to explicitly designate individuals who hold the dedicated time, professional standing, and clear mandate to reject and return AI-generated text.
As AI models advance and establish cleaner track records, human verification drops due to automation bias. A system that fails half as often, reviewed half as carefully, leaves biopharma companies in a worse position because remaining failures are subtler and masked by fluent prose. The apparent success of an AI pilot naturally lowers reviewer vigilance, allowing high-risk errors to circulate undetected.
Traditional pharma review processes implicitly depend on knowing a human author's personal habits, such as overclaiming when excited or becoming vague in regulatory sections. Generated AI text erases these fingerprints. It delivers genuine citations and fabricated claims with identical tone, fluency, and authority. Reviewers lose the intuitive mental map of where weak evidence lies, forcing an unnatural shift from noticing obvious tells to actively hunting invisible omissions.
Biopharma enterprises have poured substantial resources into teaching employees how to write AI prompts, but prompt engineering is a rapidly depreciating skill as automated model capabilities render techniques obsolete. Conversely, validating AI outputs is a permanent, non-depreciating requirement that becomes harder as models become more fluent. The industry maintains an inverted capability balance by prioritizing prompt generation over rigorous output evaluation.
Grounding AI models on approved sources effectively reduces fabricated hallucinations, but Dr Andree Bates points out it does almost nothing for distorted or misdirected outputs. In those cases, the underlying source was properly retrieved and present, yet the model dropped qualifiers, manufactured consensus, or followed conflicting prompt instructions. Grounding dictates what the system sees, not what it asserts, leaving two out of three error families unaddressed.
Distortion errors frequently disguise themselves as crisp, competent editing. When summarizing clinical documentation, an AI may compress a narrow demographic into a broad indication, expanding the patient population without explicitly stating a falsehood. Similarly, hedged statements like 'suggested' silently become 'evidence shows'. Because the resulting text is punchier and reads better, human reviewers routinely mistake substantive clinical overstatements for standard summarization.
When reviewers are conditioned to expect AI flaws, tests show that many invent non-existent errors in perfectly clean text. Over-scrutinizing creates massive business friction, slowing output without increasing safety. Rather than tripling the verification load across every draft, review rigor must be systematically calibrated according to the regulatory and clinical consequences of the document rather than a reviewer's subjective feelings of uncertainty.
